Surveillance and outbreak report Open Access
Like 0


We summarised available hepatitis C virus (HCV) surveillance data for 2012–14 from Arctic/sub-Arctic countries/regions. We sent a HCV data collection template by email to public health authorities in all jurisdictions. Population statistics obtained from census sources for each country were used to estimate rates of reported acute and chronic/undifferentiated HCV cases. Seven countries with Arctic regions (Canada, Denmark, Finland, Greenland, Norway, Sweden and the United States, represented by the state of Alaska), including three Canadian territories and one province, as well as 11 Russian subnational Arctic regions, completed the data collection template. Data on acute HCV infection during 2014 was available from three Arctic countries and all Russian Arctic regions (rate range 0/100,000 population in Greenland, as well as Nenets and Chukotka Automous Okrugs (Russian subnational Arctic regions) to 3.7/100,000 in the Russian Republic of Komi). The rate of people with chronic/undifferentiated HCV infection in 2014 ranged from 0/100,000 in Greenland to 171.2/100,000 in Alaska. In most countries/regions, the majority of HCV-infected people were male and aged 19–64 years. Differences in surveillance methods preclude direct comparisons of HCV surveillance data between Arctic countries/regions. Our data can inform future efforts to develop standardised approaches to HCV surveillance in the Arctic countries/regions by identifying similarities/differences between the surveillance data collected.


Article metrics loading...

Loading full text...

Full text loading...



  1. World Health Organization (WHO). Technical considerations and case definitions to improve surveillance for viral hepatitis: technical report. Geneva: WHO; 2016. Available from: http://www.who.int/hepatitis/publications/hep-surveillance-guide-pub/en/
  2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333-42.  https://doi.org/10.1002/hep.26141  PMID: 23172780 
  3. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1) Suppl;S45-57.  https://doi.org/10.1016/j.jhep.2014.07.027  PMID: 25086286 
  4. Nordic Council of Ministers (Norden). Arctic Human Development Report: Regional Processes and Global Linkages. Copenhagen: Norden; 2015. Available from: http://norden.diva-portal.org/smash/get/diva2:788965/FULLTEXT03.pdf
  5. Stefansson Arctic Institute. Arctic human development report. Akureyri: Stefansson Arctic Institute;2004. Available from: http://www.svs.is/en/projects/ahdr-and-asi-secretariat/ahdr-chapters
  6. Tulisov A, McMahon BJ, Koch A, Minuk G, Chulanov V, Bruce MG, et al. Viral hepatitis in the Arctic. A review from a Circumpolar Workshop on Viral hepatitis, ICCH13. Alaska Med. 2007;49(2) Suppl;193-203. PMID: 17929632 
  7. FitzSimons D, McMahon B, Hendrickx G, Vorsters A, Van Damme P. Burden and prevention of viral hepatitis in the Arctic region, Copenhagen, Denmark, 22-23 March 2012. Int J Circumpolar Health. 2013;72(1):21163.  https://doi.org/10.3402/ijch.v72i0.21163  PMID: 23971016 
  8. Arctic Council (AC). Arctic peoples. Updated 03 November 2016. Tromsø: AC; 2016. Available from: https://arctic-council.org/index.php/en/our-work/arctic-peoples
  9. Centers for Disease Control and Prevention (CDC). Surveillance for Viral Hepatitis – United States, 2000—2011. Atlanta: CDC; 2011. Available from: http://www.cdc.gov/hepatitis/Statistics/2011Surveillance/Slide4.4.htm.
  10. Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G, et al. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat. 2014;21(Suppl 1):60-89.  https://doi.org/10.1111/jvh.12249  PMID: 24713006 
  11. World Health Organization (WHO). Global health sector strategy on viral hepatitis 2016-2021 Towards ending viral hepatitis. Geneva: WHO Press; 2016. Available from: http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/
  12. Parkinson AJ, Bruce MG, Zulz T. International Circumpolar Surveillance, an Arctic network for the surveillance of infectious diseases. Emerg Infect Dis. 2008;14(1):18-24.  https://doi.org/10.3201/eid1401.070717  PMID: 18258072 
  13. National Center for Health Statistics (NCHS). Intercensal estimates of the resident population of the United States for July 1, 2000-July 1, 2009, by year, county, single-year of age (0, 1, 2., 85 years and over), bridged race, Hispanic origin, and sex. Prepared under a collaborative arrangement with the U.S. Census Bureau. [cited 2013 April 10]. Hyattsville: NCHS; Available from: http://www.cdc.gov/nchs/nvss/bridged_race.htm
  14. Zhou K, Fitzpatrick T, Walsh N, Kim JY, Chou R, Lackey M, et al. Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses. Lancet Infect Dis. 2016;16(12):1409-22.  https://doi.org/10.1016/S1473-3099(16)30208-0  PMID: 27615026 
  15. Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. Harm Reduct J. 2013;10(1):7.  https://doi.org/10.1186/1477-7517-10-7  PMID: 23651646 
  16. Duffell EF, van de Laar MJ. Survey of surveillance systems and select prevention activities for hepatitis B and C, European Union/European Economic Area, 2009. Euro Surveill. 2015;20(13):17-24. . Available from: https://doi.org/10.2807/1560-7917.ES2015.20.13.21080 https://doi.org/10.2807/1560-7917.ES2015.20.13.21080  PMID: 25860392 
  17. Rantala M, van de Laar MJ. Surveillance and epidemiology of hepatitis B and C in Europe - a review. Euro Surveill. 2008;13(21):717-27. . Available from: https://doi.org/10.2807/ese.13.21.18880-en https://doi.org/10.2807/ese.13.21.18880-en  PMID: 18761967 
  18. The Institute for Health Metrics and Evaluation (IHME). GBD Results Tool. Washington: IHME; 2017. Available from: http://ghdx.healthdata.org/gbd-results-tool
  19. U.S. Department of Health and Human Services. Action Plan for the Prevention, Care, & Treatment of Viral Hepatitis. Washington, DC: HHS; 2014. p. 1-93. Available from: https://www.hhs.gov/sites/default/files/viral-hepatitis-action-plan.pdf
  20. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378(9791):571-83.  https://doi.org/10.1016/S0140-6736(11)61097-0  PMID: 21802134 
  21. Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, McQuillan GM, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014;160(5):293-300.  https://doi.org/10.7326/M13-1133  PMID: 24737271 
  22. Tassiopoulos K, Bernstein J, Bernstein E. Age and sharing of needle injection equipment in a cohort of Massachusetts injection drug users: an observational study. Addict Sci Clin Pract. 2013;8(1):20.  https://doi.org/10.1186/1940-0640-8-20  PMID: 24330568 
  23. Zibbell JE, Iqbal K, Patel RC, Suryaprasad A, Sanders KJ, Moore-Moravian L, et al. Increases in hepatitis C virus infection related to injection drug use among persons aged ≤30 years - Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012. MMWR Morb Mortal Wkly Rep. 2015;64(17):453-8. PMID: 25950251 

Data & Media loading...

Submit comment
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error